VERAXA Biotech Reports Proof-of-Concept Data for BiTAC-ADC Platform, Enhancing Cancer Therapy Precision

VERAXA Biotech AG (NASDAQ: VRXA) has announced new in vitro proof-of-concept data supporting its BiTAC(TM)-ADC technology platform, a novel approach designed to improve precision in cancer treatment. The company reported that BiTAC-ADCs successfully distinguished between breast cancer cells and healthy cells, achieving dose-dependent killing of 3D tumor cell spheroids while minimizing toxicity through the use of separately delivered, systemically inactive precursor components.

The findings further validate the potential of VERAXA's BiTAC-ADC platform, which complements its existing BiTAC-TCE technology. Together, these two differentiated platforms may be applicable across multiple solid tumor indications, offering a versatile approach to cancer therapy. VERAXA management plans to discuss partnering opportunities for both platforms at the BIO International Convention in San Diego from June 22-25, 2026, as noted in the press release available at https://ibn.fm/QiPhH.

The BiTAC-ADC technology represents a significant advancement in antibody-drug conjugate design. By requiring two separate components to combine only at the tumor site, the platform aims to reduce off-target effects common with traditional ADCs. This tumor-restricted activation could lead to higher therapeutic indices and improved patient outcomes. VERAXA's approach builds on scientific breakthroughs from the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research.

VERAXA Biotech is building a premier engine for next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. The company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development. The proof-of-concept data for BiTAC-ADC strengthens the company's position in the competitive oncology landscape, where precision and reduced toxicity are key goals.

The implications of this announcement are broad. For investors, the data provides evidence of platform viability, potentially increasing the likelihood of future partnerships and funding. For the medical community, BiTAC-ADCs could offer a new tool against solid tumors that are difficult to treat with conventional therapies. The company's focus on quality-by-design principles ensures rigorous development standards.

VERAXA's participation at the BIO International Convention will be a critical opportunity to showcase these platforms to potential partners. The company's newsroom at http://ibn.fm/VRXA provides updates on ongoing developments. As VERAXA moves toward clinical trials, the success of its BiTAC platforms could reshape treatment paradigms for cancer patients worldwide.